New unsymmetrical bisacridines (UAs) demonstrated high activity not only against a set of
tumor cell lines but also against human tumor xenografts in nude mice. Representative UA …

Unsymmetrical bisacridines (UAs) are a novel potent class of antitumor-active therapeutics.
A significant route of phase II drug metabolism is conjugation with glutathione (GSH), which …

The development of a new drug requires knowledge about its metabolic fate in a living
organism, regarding the comprehensive assessment of both drug therapeutic activity and …

Electrochemistry (EC) coupled with analysis techniques such as liquid chromatography (LC)
and mass spectrometry (MS) has been developed as a powerful tool for drug metabolism …

Unsymmetrical bisacridines (UAs) represent a novel class of anticancer agents previously
synthesized by our group. Our recent studies have demonstrated their high antitumor …

This work is the next step in studying the interplay between C-2028 (anticancer-active
unsymmetrical bisacridine developed in our group) and the glutathione S-transferase …

Activity modulation of drug metabolism enzymes can change the biotransformation of
chemotherapeutics and cellular responses induced by them. As a result, drug-drug …

Background Among the studied antitumor acridinone derivatives developed in our
laboratory, 5-dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) and 5 …

The effectiveness of many anticancer drugs depends on the creation of specific metabolites
that may alter their therapeutic or toxic properties. One significant route of biotransformation …

Unsymmetrical bisacridines (UAs) are highly active antitumor compounds. They contain in
their structure the drugs previously synthesized in our Department: C-1311 and C-1748. UAs …